Sequential Adjuvant Chemotherapy With Doxorubicin, Taxol, and Cyclophosphamide for Stage II or III Resectable Breast Cancer With Four or More Involved Axillary Lymph Nodes
OBJECTIVES: I. Evaluate the efficacy of dose intensive, sequential adjuvant chemotherapy
with doxorubicin, paclitaxel, and cyclophosphamide in patients with stage II/III resected
breast cancer. II. Evaluate the toxicity of this regimen in these patients.
OUTLINE: All patients receive sequential chemotherapy regimens consisting of 3 courses each
of doxorubicin, paclitaxel, and cyclophosphamide on a schedule of one course every 14 days.
Following completion of chemotherapy, patients who underwent breast conservation surgery
receive radiotherapy. Mastectomy patients with 10 or more positive nodes or with T3-4 tumors
are also eligible for delayed radiotherapy. Patients who are hormone receptor positive (or
whose receptor status is unknown) are treated with oral tamoxifen for 5 years, beginning
after completion of all other therapy. Patients are followed every 3 months for 2 years,
every 6 months for 3 years, then yearly.
PROJECTED ACCRUAL: At total of 90 patients will be entered.
Primary Purpose: Treatment
Maysa Abu-Khalaf, MD
United States: Federal Government
|Yale Comprehensive Cancer Center||New Haven, Connecticut 06520-8028|